[go: up one dir, main page]

Gunduz et al., 1983 - Google Patents

Fluoresceinated estrone binding by cells from human breast cancers obtained by needle aspiration

Gunduz et al., 1983

View PDF
Document ID
2692520962968223084
Author
Gunduz N
Zheng S
Fisher B
Publication year
Publication venue
Cancer

External Links

Snippet

Despite widespread use there are disadvantages associated with biochemical methods for ER determination. Since there is increasing emphasis on earlier detection of primary breast cancers there is clearly a need for a method which requires only small numbers of tumor …
Continue reading at acsjournals.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation

Similar Documents

Publication Publication Date Title
Xu et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and-nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material
AU689248B2 (en) A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
Darzynkiewicz et al. Difficulties and pitfalls in analysis of apoptosis
JP4768005B2 (en) Compositions and methods for detecting precancerous conditions in cell and tissue samples using 5,10,15,20-tetrakis (carboxyphenyl) porphine
Diamond et al. Flow analysis of DNA content and cell size in non-Hodgkin's lymphoma
EP1861509B1 (en) A method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
Iversen et al. Ploidy assessment of benign and malignant ovarian tumors by flow cytometry. A clinicopathologic study
Sneige et al. Fine-needle aspiration cytology of ductal hyperplasia with and without atypia and ductal carcinoma in situ
WO2000047998A1 (en) Class characterization of circulating cancer cells isolated from body fluids and methods of use
Makris et al. Cytological evaluation of biological prognostic markers from primary breast carcinomas
US20050250155A1 (en) Multiple marker characterization of single cells
Pertschuk et al. Histochemical assay of estrogen and progesterone receptors in breast cancer: Correlation with biochemical assays and patients' response to endocrine therapies
Brünagel et al. Nuclear matrix protein alterations associated with colon cancer metastasis to the liver
EP1221053A2 (en) A method for isolation of prostatic epithelial cells from semen
Garcia et al. Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification
Greene et al. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features
Gunduz et al. Fluoresceinated estrone binding by cells from human breast cancers obtained by needle aspiration
Eibling et al. Flow cytometric evaluation of adenoid cystic carcinoma: correlation with histologic subtype and survival
Kang et al. A handheld device for potential point-of-care screening of cancer
Panko et al. Lack of correlation of a histochemical method for estrogen receptor analysis with the biochemical assay results
Pertschuk et al. Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up
Linden et al. Flow cytometric prescreening of cervical smears.
Hermansen et al. Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin)
Schurman et al. Improved detection of metastases to lymph nodes and estrogen receptor determination
JP2012506048A (en) A preclinical method for monitoring continuous changes in circulating breast cancer cells in mice